玮俊生物科技(00660)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00660 玮俊生物科技

交易中 04-15 15:58:08

1.250

-1.050

-45.65%

最高2.300	最低1.120	成交量2,018万
今开2.080	昨收2.300	日振幅51.30%
总市值2.23亿	流通市值2.23亿	总股本1.78亿
成交额3,028万	换手率11.34%	流通股本1.78亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00660","market":"HK","secType":"STK","nameCN":"玮俊生物科技","latestPrice":1.25,"timestamp":1776239885125,"preClose":2.3,"halted":0,"volume":20182000,"delay":0,"changeRate":-0.45652173913043476,"floatShares":178000000,"shares":178000000,"eps":-0.084305,"marketStatus":"交易中","change":-1.05,"latestTime":"04-15 15:58:08","open":2.08,"high":2.3,"low":1.12,"amount":30281293,"amplitude":0.513043,"askPrice":1.26,"askSize":20000,"bidPrice":1.25,"bidSize":60000,"shortable":0,"etf":0,"ttmEps":-0.039,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1776240600000},"marketStatusCode":2,"adr":0,"listingDate":728841600000,"exchange":"SEHK","adjPreClose":2.3,"openAndCloseTimeList":[[1776216600000,1776225600000],[1776229200000,1776240000000]],"volumeRatio":2.81043,"lotSize":20000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00660","defaultTab":"news","newsList":[{"id":"2627471622","title":"港股异动 | 玮俊生物科技(00660)回落超40% 日前披露新能源大计股价暴涨8倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2627471622","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627471622?lang=zh_cn&edition=full","pubTime":"2026-04-15 10:20","pubTimestamp":1776219635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，玮俊生物科技回落超40%，该股昨日复牌大涨，最终收涨超800%。截至发稿，跌40.87%，报1.36港元，成交额2109.48万港元。消息面上，玮俊生物科技日前公布，4月12日，公司作为总牵头方及控股方，与多家中国大型央企、海外知名跨国巨头及国际顶级金融机构联合签署了《新能源项目战略合作备忘录》。合作各方将在全球范围内共同投资、开发、建设和运营风力及太阳能发电等新能源项目。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","159875","BK4585","BK1237","000941.SH","00660","160640","BK4588","399941"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627467767","title":"玮俊生物科技公布将于4月14日上午起复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2627467767","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627467767?lang=zh_cn&edition=full","pubTime":"2026-04-14 08:58","pubTimestamp":1776128280,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　玮俊生物科技（00660）发布公告，该公司股份将于2026年4月14日上午9时正起恢复买卖。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-04-14/doc-inhummye5010460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1237","00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627737433","title":"玮俊生物科技(00660)与大型央企及国际巨头强强联合 签署《新能源项目战略合作备忘录》","url":"https://stock-news.laohu8.com/highlight/detail?id=2627737433","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627737433?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:37","pubTimestamp":1776069469,"startTime":"0","endTime":"0","summary":"智通财经APP讯，玮俊生物科技 公布，于2026年4月12日，该公司作为总牵头方及控股方，与多家中国大型央企(央企)、海外知名跨国巨头及国际顶级金融机构联合签署了《新能源项目战略合作备忘录》。合作各方将成立由公司牵头的联合工作组，定期召开推进会并锁定项目资源。董事会认为，本次战略合作备忘录的签署，是集团发展史上的最重大里程碑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000941.SH","159875","399941","00660","BK1237","160640"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156166472","title":"玮俊生物科技锁定全球九大市场：泰国、印尼、中亚、美加、罗马尼亚、沙特、赞比亚、蒙古","url":"https://stock-news.laohu8.com/highlight/detail?id=1156166472","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156166472?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:37","pubTimestamp":1776069429,"startTime":"0","endTime":"0","summary":"玮俊生物科技正加速推进其全球化战略布局，计划将业务版图拓展至包括泰国、印度尼西亚在内的东南亚市场，并同步进军中亚地区。与此同时，北美市场的美国与加拿大、欧洲的罗马尼亚、中东的沙特阿拉伯，以及非洲的赞比亚和东亚的蒙古，均被纳入其重点目标区域。这一系列举措彰显了公司打造跨国产业链的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1237","00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181142220","title":"玮俊生物科技携手韩国新能源项目 开发规模不低于500亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181142220","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181142220?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:35","pubTimestamp":1776069314,"startTime":"0","endTime":"0","summary":"玮俊生物科技有限公司宣布，将在韩国推进一系列新能源项目的开发，总投资规模预计不低于500亿美元。这一重大举措标志着公司正式进军新能源领域，展现了其拓展业务版图的战略决心。\n项目规划显示，此次合作将聚焦于可再生能源技术的创新与应用，旨在推动绿色能源产业的发展。业界分析认为，如此大规模的投资将对全球新能源市场格局产生深远影响，并为公司带来新的增长机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1237","00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191523428","title":"玮俊生物科技与多家央企及国际伙伴签署新能源项目战略合作备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=1191523428","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191523428?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:35","pubTimestamp":1776069311,"startTime":"0","endTime":"0","summary":"玮俊生物科技近日宣布，公司已与数家中央企业及全球合作伙伴共同签署了一份关于新能源项目的战略合作备忘录。这一重要举措标志着该公司正式进军新能源领域，旨在通过多方协作推动相关项目的开发与实施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00660","BK1237"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627020671","title":"玮俊生物科技(00660)4月13日起短暂停牌 原因待公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2627020671","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627020671?lang=zh_cn&edition=full","pubTime":"2026-04-13 08:56","pubTimestamp":1776041816,"startTime":"0","endTime":"0","summary":"智通财经APP讯，玮俊生物科技(00660)发布公告，该公司股份将于2026年4月13日上午9时正起短暂停止买卖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1237","00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130749921","title":"玮俊生物科技3月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1130749921","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130749921?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:11","pubTimestamp":1775722269,"startTime":"0","endTime":"0","summary":"玮俊生物科技于2026年4月9日发布截至2026年3月31日的股份变动月报表。公告显示，公司当前法定股本总额为102,040,000港元，其中普通股10,000,000,000股对应100,000,000港元，优先股204,000,000股对应2,040,000港元，均较上月保持不变。公司披露，购股权计划下共15,954,685份购股权继续有效，月内无行使或失效情形，因此未增发任何新股。公告还提及现有多笔可换股债券，但本月未有实际转换或导致已发行股份数变化，公司股本架构总体保持稳定。本次公告由执行董事林家俊签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101930314","title":"玮俊生物科技2025/26中期营收3.52亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101930314","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101930314?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:36","pubTimestamp":1774859816,"startTime":"0","endTime":"0","summary":"玮俊生物科技公告显示，截至2025年12月31日止六个月，公司实现营收约3.52亿港元，同比增长约118.7%。同期毛利达到约1,310万港元，较上年同期约1,010万港元增长近30%，毛利率从35.7%下降至21.1%。经营活动所带来的现金净流入约2,241万港元，上年同期则仅为约5万港元。玮俊生物科技主要从事变性淀粉及其他生化产品的制造与销售。报告期内，变性淀粉及相关生化产品的需求显著提升，带动整体收入大幅增长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186299768","title":"玮俊生物宣布再度延迟通函寄发　将改以召开股东大会审议提款事项","url":"https://stock-news.laohu8.com/highlight/detail?id=1186299768","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186299768?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:56","pubTimestamp":1774608975,"startTime":"0","endTime":"0","summary":"玮俊生物科技有限公司3月27日晚间发布补充公告，披露有关贷款协议及不合规事宜的通函寄发时间再度延迟，并决定转而召开股东大会以审批相关提款事项。按最初安排，玮俊生物已取得持股约51.30%的大股东中国成功有限公司书面同意，计划依据《上市规则》第14.44条，以书面股东批准方式通过提款决议。然而，因编制通函所需时间超过预期，玮俊生物未能如期寄发，并决定改采召开股东大会的方式审议提款事项。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618671230","title":"玮俊生物科技盘中异动 早盘股价大跌10.38%报0.233港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618671230","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618671230?lang=zh_cn&edition=full","pubTime":"2026-03-09 10:06","pubTimestamp":1773021999,"startTime":"0","endTime":"0","summary":"2026年03月09日早盘10时06分，玮俊生物科技股票出现波动，股价急速下挫10.38%。截至发稿，该股报0.233港元/股，成交量2万股，换手率0.01%，振幅0.00%。资金方面，该股资金流入0港元，流出4660港元。玮俊生物科技股票所在的特殊化工用品行业中，整体跌幅为0.86%。玮俊生物科技公司简介：玮俊生物科技有限公司是一家主要从事制造及销售变性淀粉的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030910063997aaa60f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030910063997aaa60f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00660","BK1237"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617545224","title":"玮俊生物科技(00660)：何小萍获委任为公司秘书和授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2617545224","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617545224?lang=zh_cn&edition=full","pubTime":"2026-03-05 19:02","pubTimestamp":1772708521,"startTime":"0","endTime":"0","summary":"智通财经APP讯，玮俊生物科技(00660)发布公告，何小萍女士获委任为根据上市规则第3.28条及第3.05条下的公司秘书和授权代表，自2026年3月5日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00660","BK1237"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102890061","title":"玮俊生物科技（00660）2月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1102890061","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102890061?lang=zh_cn&edition=full","pubTime":"2026-03-04 15:01","pubTimestamp":1772607693,"startTime":"0","endTime":"0","summary":"玮俊生物科技有限公司于2026年3月4日发布截至2026年2月28日的股份变动月报。公告显示，公司当前法定/注册股本包括普通股与可换股优先股，普通股法定/注册股本为100,000,000港元，优先股法定/注册股本为2,040,000港元，合计102,040,000港元，较上月无变化。已发行股份方面，截至2月底，公司普通股数量为178,476,453股，报告期内无新增发行、回购或注销，库存股数量保持为0股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614314058","title":"玮俊生物科技(00660)发布中期业绩，股东应占亏损593.9万港元 同比减少56.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614314058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614314058?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:24","pubTimestamp":1772187848,"startTime":"0","endTime":"0","summary":"智通财经APP讯，玮俊生物科技(00660)发布截至2025年12月31日止6个月的中期业绩，该公司取得收入3.52亿港元，同比增加118.65%;归属于公司拥有人期内亏损593.9万港元，同比减少56.53%;每股亏损3.33港仙。公告称，收入增加乃由于期间市场消费和需求增加。本集团截至2025年12月31日止6个月取得的毛利及毛利率分别约3570万港元及10.1%，截至2024年12月31日止6个月所取得的毛利约2110万港元及毛利率约13.1%，期间增加约1450万港元及减少3.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1237","00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164216706","title":"瑋俊生物科技2026财年上半年营收3.52亿元，经调整净亏损0.06亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164216706","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164216706?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:21","pubTimestamp":1772187675,"startTime":"0","endTime":"0","summary":"瑋俊生物科技有限公司公布截至2025年12月31日止六个月的中期业绩，报告期内实现营收3.52亿元港币，同比增加118.7%。毛利约0.36亿元港币，较上年同期约0.21亿元港币提高约68.8%，但毛利率从13.1%下降至10.1%。管理层指出，销售费用约0.15亿元港币，同比上升181.9%；行政费用约0.15亿元港币，同比上升22.8%。财务成本则由上年同期约0.10亿元港币降至约0.05亿元港币，主要由于相关债务条款变化带来的利息支出减少。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614015641","title":"玮俊生物科技盘中异动 急速下跌7.14%报0.260港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614015641","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614015641?lang=zh_cn&edition=full","pubTime":"2026-02-26 10:27","pubTimestamp":1772072846,"startTime":"0","endTime":"0","summary":"2026年02月26日早盘10时27分，玮俊生物科技股票出现异动，股价快速下跌7.14%。截至发稿，该股报0.260港元/股，成交量0股，换手率0.00%，振幅0.00%。资金方面，该股资金流入1.03万港元，流出0港元。玮俊生物科技股票所在的特殊化工用品行业中，整体涨幅为0.41%。玮俊生物科技公司简介：玮俊生物科技有限公司是一家主要从事制造及销售变性淀粉的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022610272695420769&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022610272695420769&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00660","BK1237"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614080437","title":"玮俊生物科技(00660.HK)：预计中期净亏损不超过600万港元 同比大幅减少","url":"https://stock-news.laohu8.com/highlight/detail?id=2614080437","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614080437?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:37","pubTimestamp":1772026621,"startTime":"0","endTime":"0","summary":"格隆汇2月25日丨玮俊生物科技(00660.HK)公告，根据对集团截至2025年12月31日止六个月未经审核综合管理账目的初步评估，集团预期于截至2025年12月31日止六个月录得之净亏损不超过600万港元，亏损相比截至2024年12月31止六个月之净亏损约1310万港元大幅减少。亏损大幅减少之主要原因为报告期内营业额的上升及财务成本的减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260225/32027244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1237","00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100209115","title":"玮俊生物科技中期业绩预增 主因营收上升与财务成本下降","url":"https://stock-news.laohu8.com/highlight/detail?id=1100209115","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100209115?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:24","pubTimestamp":1772025845,"startTime":"0","endTime":"0","summary":"玮俊生物科技有限公司（股票代码：00660）预计中期业绩将实现增长。这一积极预期主要得益于公司营收的显著提升以及财务成本的持续下降。营收增长反映了公司核心业务的强劲表现，而财务成本的控制则优化了整体盈利结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1237","00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156694708","title":"瑋俊生物科技有限公司2025年下半年营收上升，净利润-6.0百万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156694708","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156694708?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:21","pubTimestamp":1772025704,"startTime":"0","endTime":"0","summary":"本期信息\n瑋俊生物科技有限公司（股份代號：660）发布截至2025年12月31日止六个月的中期业绩预告，期内净亏损不超过6.0百万港元，相比2024年同期的约13.1百万港元，亏损幅度大幅收窄。公司方面指出，本期亏损显著减少主要得益于营业额的上升以及财务成本的下降。\n业务分项\n公告中强调，该集团在报告期内营收增长，带动整体业绩改善。同时，财务成本的减少也对盈利能力提升带来正面影响。由于公告未披露其他具体业务板块的营收或经营指标，暂未进一步拆分展示。\n高管解读\n（公告未提供相关高管原话）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00660"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614083936","title":"玮俊生物科技(00660)及第一被告已向香港高等法院提交上诉通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083936","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614083936?lang=zh_cn&edition=full","pubTime":"2026-02-25 18:53","pubTimestamp":1772016834,"startTime":"0","endTime":"0","summary":"智通财经APP讯，玮俊生物科技 发布公告，于2026年2月13日，本公司接获香港特别行政区高等法院原讼法庭日期为2026年2月13日针对本公司及伟俊集团控股有限公司作出的一项盖印判决书。于本公告日期，本公司及第一被告已向香港高等法院提交上诉通知书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00660","BK1237"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.0660.hk","stockEarnings":[{"period":"1week","weight":8.0196},{"period":"1month","weight":8.7872},{"period":"3month","weight":10.7949},{"period":"6month","weight":10.7949},{"period":"1year","weight":29.2632},{"period":"ytd","weight":11.234}],"compareEarnings":[{"period":"1week","weight":0.0301},{"period":"1month","weight":0.016},{"period":"3month","weight":-0.0418},{"period":"6month","weight":-0.0006},{"period":"1year","weight":0.208},{"period":"ytd","weight":0.0094}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"玮俊生物科技有限公司是一家主要从事制造及销售变性淀粉的香港投资控股公司。该公司连同其附属公司主要从事制造及销售变性淀粉及其他生化产品,例如生化精炼油产品。此外，该公司还从事买卖电子元件、组件和器件及电器。","yearOnYearQuotes":[{"month":1,"riseRate":0.393939,"avgChangeRate":0.06724},{"month":2,"riseRate":0.424242,"avgChangeRate":0.11624},{"month":3,"riseRate":0.294118,"avgChangeRate":0.093297},{"month":4,"riseRate":0.30303,"avgChangeRate":0.279845},{"month":5,"riseRate":0.4375,"avgChangeRate":0.013691},{"month":6,"riseRate":0.515152,"avgChangeRate":0.046961},{"month":7,"riseRate":0.30303,"avgChangeRate":0.024464},{"month":8,"riseRate":0.181818,"avgChangeRate":-0.035696},{"month":9,"riseRate":0.242424,"avgChangeRate":-0.048197},{"month":10,"riseRate":0.34375,"avgChangeRate":0.029107},{"month":11,"riseRate":0.28125,"avgChangeRate":-0.01241},{"month":12,"riseRate":0.212121,"avgChangeRate":-0.037096}],"exchange":"SEHK","name":"玮俊生物科技","nameEN":"WAI CHUN BIOTEC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"玮俊生物科技(00660)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供玮俊生物科技(00660)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"玮俊生物科技,00660,玮俊生物科技股票,玮俊生物科技股票老虎,玮俊生物科技股票老虎国际,玮俊生物科技行情,玮俊生物科技股票行情,玮俊生物科技股价,玮俊生物科技股市,玮俊生物科技股票价格,玮俊生物科技股票交易,玮俊生物科技股票购买,玮俊生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"玮俊生物科技(00660)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供玮俊生物科技(00660)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}